Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer.
AuthorsBoard, Ruth E
Wardley, Andrew M
Dixon, J Michael
Armstrong, Anne C
Howell, Sacha J
Ranson, Malcolm R
AffiliationClinical and Experimental Pharmacology Group, Paterson Institute for Cancer Research, University of Manchester, Manchester, M20 4BX, UK.
MetadataShow full item record
AbstractSomatic mutations in PIK3CA (encoding a class I phosphoinositide 3 kinase (PI3K) subunit) modulate PI3K signalling to influence tumour behaviour and occur in up to 40% of breast cancers. Inhibitors of PI3K signalling are entering clinical trials, but the impact of PIKC3A mutation on tumour response has yet to be clarified. This study investigated the potential utility of circulating free DNA (cfDNA) as a source for PIK3CA mutation detection in patients with breast cancer. cfDNA extracted (QIAamp Virus spin kit) from blood and matched archival tumour from 46 patients with metastatic breast cancer and 30 patients with localised, operable breast cancer was assessed for hotspot PIK3CA mutations using Amplification Refractory Mutation System (ARMS()) allele-specific PCR and Scorpion probes. PIK3CA mutations were detected in 13/46 (28%) plasma-derived and 10/46 (21%) serum-derived cfDNA samples from metastatic breast cancer patients. In 41 cases with matched tumour and plasma-derived cfDNA data, concordance (same mutation status in plasma and tumour) was 95%. Where a PIK3CA mutation was present in tumour, the 'pick up' in plasma-derived cfDNA was 80%. PIK3CA mutations were present in tumours from 14/30 (47%) localised breast cancers, but no PIK3CA mutations were detected in matched cfDNA. These data demonstrate feasibility and potential utility of cfDNA for PIK3CA mutation detection in patients with metastatic breast cancer. Studies are underway to qualify PIK3CA mutation in cfDNA as a predictive biomarker allowing patient stratification in clinical trials of mechanism-based therapeutics that target PI3K signalling pathways.
CitationDetection of PIK3CA mutations in circulating free DNA in patients with breast cancer. 2010, 120 (2):461-7 Breast Cancer Res. Treat.
JournalBreast Cancer Research and Treatment
- PIK3CA mutation associates with improved outcome in breast cancer.
- Authors: Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, Hedvat CV, Traina TA, Solit D, Gerald W, Moynahan ME
- Issue date: 2009 Aug 15
- A novel PIK3CA hotspot mutation in Isfahanian breast cancer patients.
- Authors: Gharbi S, Faghihi M, Tavassoli M
- Issue date: 2011 May
- PIK3CA mutations rarely demonstrate genotypic intratumoral heterogeneity and are selected for in breast cancer progression.
- Authors: Kalinsky K, Heguy A, Bhanot UK, Patil S, Moynahan ME
- Issue date: 2011 Sep
- TP53 mutations in circulating free DNA from Egyptian patients with non-Hodgkin's lymphoma.
- Authors: Hosny G, Farahat N, Hainaut P
- Issue date: 2009 Mar 18
- ESR1 and PIK3CA mutational status in serum and plasma from metastatic breast cancer patients: A comparative study.
- Authors: Takeshita T, Yamamoto Y, Yamamoto-Ibusuki M, Tomiguchi M, Sueta A, Iwase H
- Issue date: 2018